

Systematic mutation reveals different phospho-interaction patterns of beta-arrestin-1 to GPR35 and GPR120

L. Lin, A. Tobin, G. Milligan. Institute of Molecular, Cell and Systems Biology, Glasgow, United Kingdom.

Introduction: Decreased G protein-coupled receptor (GPCR) internalization or highly-activated β -arrestin-biased signalling is closely associated to diseases such as cardiovascular disease or cancer respectively [1,2]. Further investigation of GPCR- β -arrestin interaction may therefore be important for understanding the mechanism(s) involving in the development and progression of these diseases. Currently, the receptor phospho-barcode and how this modulates the interaction pattern with β -arrestins are poorly understood. In a previous report, seven phosphate-binding sites of β -arrestin-1 were identified by an NMR approach [3]. Here, we have generated seven β -arrestin-1 mutants corresponding to these sites and demonstrate: 1) GPR35 and GPR120 interact with different phosphate-binding sites of β -arrestin-1; 2) some mutations of β -arrestin-1 lead to greater levels of GPCR- β -arrestin-1 interaction.

Methods: GPR35 and GPR120 receptor constructs contained enhanced yellow fluorescent protein (eYFP) fused to the C terminus as previously described [4,5]. Constructs of wild type and mutant bovine β -arrestin-1 with NanoLuc luciferase fused to their N terminus were generated and applied in bioluminescence resonance energy transfer (BRET) assays. β -arrestin-1 mutations include site1 (Y63A/R65A/K77A), site2 (K160A/R65A/R165A), site3 (K160A/K11A), site4 (R25A), site5 (R7A), site6 (R7A), and site6/7 (Y21A/K107A/K10E). Agonists applied here were zaprinast for GPR35 and TUG-891 for GPR120. Results represent the mean \pm SEM.

Results: Results are shown as Table 1:

- 1) GPR35 interacts with sites 1, 2, 3, 4 of β -arrestin-1, whereas GPR120 interacts with sites 2, 3, 6.
- 2) Site 7 displays species selective β -arrestin-1 interactions between mouse and human GPR35
- 3) Site 6 or sites 1, 5 significantly increase β -arrestin-1 interactions with GPR35 or GPR120 respectively.

Table 1. β -arrestin-1 recruitment (% max WT response).

	WT	SITE1	SITE2	SITE3	SITE4	SITE5	SITE6	SITE6/7
h35	100.0 \pm 5.0	33.8 \pm 3.6	46.0 \pm 5.0	15.8 \pm 4.0	59.7 \pm 2.7	100.7 \pm 1.5	140.0 \pm 1.4	196.4 \pm 7.7
m35	100.0 \pm 3.1	53.8 \pm 7.8	51.3 \pm 4.2	17.7 \pm 2.5	29.0 \pm 2.8	109.7 \pm 4.0	188.5 \pm 3.4	69.9 \pm 3.0
h120	100.0 \pm 3.4	177.8 \pm 0.3	66.3 \pm 0.3	61.4 \pm 2.8	126.7 \pm 6.4	200.1 \pm 4.7	73.9 \pm 1.9	106.6 \pm 7.5
m120	100.0 \pm 0.2	158.9 \pm 1.4	52.1 \pm 2.9	47.7 \pm 2.3	113.7 \pm 0.9	137.4 \pm 0.8	78.8 \pm 2.6	123.3 \pm 5.2

Conclusions: β -arrestin-1 displays different phospho-interaction patterns with GPR35 and GPR120. These differences may allow β -arrestin-1 to activate different downstream targets and contribute to the functional diversity of GPCR receptors in their control of physiological responses.

References:

1. Carr et al. (2016) *Proc Natl Acad Sci U S A*. **113**:E4107-E4116.
2. Kose et al. (2017) *Bioorganic & Medicinal Chemistry Letters*. **27**:3611-3620.
3. Yang et al. (2015) *Nat Commun*. **6**:8202.
4. Jenkins et al. (2011) *Br J Pharmacol*. **162**:733-748.
5. Hudson et al. (2013) *Mol Pharmacol*. **84**:710-725.